EDMONTON, Canada--(BUSINESS WIRE)--iTraumaCare®, an early-stage medical device company focused on developing traumatic injury solutions for first responder, emergency medicine and military medicine applications, announced today that its iTClamp® Hemorrhage Control System has been recommended by the U.S. Department of Defense’s Committee on Tactical Combat Casualty Care (CoTCCC).
CoTCCC recommends the use of the iTClamp as a primary option for external hemorrhage of the head and neck, and as an alternative adjunct for massive compressible external hemorrhage not amenable to limb tourniquet use or as an adjunct to tourniquet removal.
“CoTCCC’s decision to include the iTClamp in its recommendations is driven by the need for a hemorrhage control tool that addresses life threatening bleeding from the head and neck region. This is a strong validation of the quality and effectiveness of our device,” commented Joe Brennan, CEO of Innovative Trauma Care. “Multiple independent and peer-reviewed studies have shown that the iTClamp is an excellent choice for controlling hemorrhage in both military and civilian applications, and we look forward to greatly expanding use of the iTClamp across a wide variety of scenarios.”
The iTClamp Hemorrhage Control System has FDA 510(k) clearance and is designed to control bleeding in seconds in the scalp, neck, extremities, groin and axilla areas. The iTClamp seals the edges of a wound closed to create a temporary hematoma under pressure that mitigates further blood loss until the wound can be surgically repaired.
Incorporated in 2010 and based in Edmonton, Canada, iTraumaCare is addressing unmet needs in the fields of emergency and military medicine by developing, manufacturing, and commercializing solutions to treat common causes of preventable death in traumatic injury scenarios.
